Compare EHI & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHI | QTRX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 160.0M |
| IPO Year | 2003 | 2017 |
| Metric | EHI | QTRX |
|---|---|---|
| Price | $5.69 | $2.73 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 183.7K | ★ 862.1K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,632,000.00 |
| Revenue This Year | N/A | $25.49 |
| Revenue Next Year | N/A | $10.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $5.68 | $2.15 |
| 52 Week High | $6.70 | $8.77 |
| Indicator | EHI | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 45.17 |
| Support Level | N/A | $2.40 |
| Resistance Level | $6.03 | $3.99 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 9.86 | 38.41 |
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income. The Fund's secondary investment objective is total return. It invests in an international portfolio of securities consisting of below-investment-grade fixed income securities, emerging market fixed income securities, and investment-grade fixed income securities. The Fund's investment portfolio comprises sovereign bonds, collateralized mortgage obligations, asset-backed securities, and fixed income securities from different corporate sectors, including financials, energy, consumer discretionary, and industrials, among others.
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.